癌症免疫疗法

Cancer immunotherapy.

作者信息

White Richard L, Amin Asim

机构信息

Division of Surgical Oncology, Carolinas Medical Center, Blumenthal Cancer Center, 1025 Morehead Medical Drive, Suite 600, Charlotte, NC 28204, USA.

出版信息

Surg Oncol Clin N Am. 2011 Jul;20(3):531-54, ix. doi: 10.1016/j.soc.2011.01.010.

DOI:10.1016/j.soc.2011.01.010

PMID:21640920

Abstract

Immune-based therapies for cancer are now commonplace. Cytokine therapy, including interferon and interleukin-2, is safe in the community setting. The US Food and Drug Administration has recently approved sipuleucel-T for the treatment of advanced prostate cancer, the first therapeutic cancer vaccine to meet this level of efficacy. The therapeutic use of monoclonal antibodies directed against proteins controlling various cell functions, including growth and modulation of immune response, has become so pervasive that the oncologist, whether surgeon or medical oncologist, must be familiar with indications, contraindications, and the associated toxicities.

摘要

基于免疫的癌症治疗方法如今已很常见。细胞因子疗法，包括干扰素和白细胞介素 - 2，在社区环境中是安全的。美国食品药品监督管理局最近批准了西妥昔单抗用于治疗晚期前列腺癌，这是首个达到这种疗效水平的治疗性癌症疫苗。针对控制各种细胞功能（包括生长和免疫反应调节）的蛋白质的单克隆抗体的治疗用途已经非常普遍，以至于肿瘤学家，无论是外科医生还是医学肿瘤学家，都必须熟悉其适应证、禁忌证以及相关毒性。